In another pilot study, SGLT2 inhibitors induced a reduction in urinary SOD and MnSOD activity, as well as in total antioxidant capacity, in individuals with type 2 diabetes mellitus [89]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.